A practical buyer-underwriting guide for physician owners evaluating who acquires medical practices, how buyer types differ, what each buyer underwrites, and how buyer fit affects valuation, deal structure, diligence, rollover, employment terms, cash at close, and certainty of close.
By George Barsom, JD, CM&AA®, CAIA® • Last updated: June 8, 2026 Updated for physician owners, specialty practice groups, healthcare operators, and referring professionals evaluating specialty physician practice M&A, buyer underwriting, specialty-specific valuation drivers, platform versus add-on positioning, rollover equity, earnouts, working-capital mechanics, and seller proceeds. This article is informational and is not legal, tax, accounting, investment,…
A buyer-focused guide to how power and utility engineering firms are valued in M&A, including the operating drivers, contract-level risks, multiple adjustments, and deal-structure terms that shape enterprise value and seller proceeds.
A founder-focused decision framework for choosing between a full exit and a partial business sale, with practical guidance on liquidity, control, retained upside, buyer expectations, and the situations where each path tends to make the most strategic sense.
A practical seller-side guide to turning valuation work into a marketable asking price. This article explains how buyers underwrite price, how owners should set an anchor and reserve, and how structure, messaging, and proceeds mechanics affect buyer interest and negotiation leverage.
A buyer-focused guide to how acquisition teams use valuation calculators in practice: first-pass screening, EBITDA normalization, multiple sensitivity, EV-to-equity bridge logic, and the thresholds that determine whether a deal advances to underwriting.
Online valuation tools can be useful for initial range-setting, but they rarely survive live buyer underwriting unchanged. This article explains the exact diligence findings and SPA mechanics that cause calculator outputs to diverge from enterprise value, equity value, and cash at close in real middle-market deals.
Many companies do not fail to sell because there is no buyer universe. They fail because buyers cannot underwrite durable cash flow, transferable operations, and manageable diligence risk at an acceptable price and structure.
Strategic buyers can justify paying more than financial sponsors, but premium pricing only holds when synergies are real, executable, and durable. This article explains how overpayment happens, why it backfires in live transactions, and what sellers should understand when a strategic bid looks unusually aggressive.
A signed letter of intent may set a headline price, but it rarely fixes final seller economics. This article explains where value moves between LOI and close, how buyers re-underwrite risk during diligence, and why transaction structure often matters as much as the top-line number.